La dermatite atopique aggrave l’inflammation allergique dans la bronchiolite aiguë virale

Marchand, D. Le; Tayara, N.; Choukroun, M.L.; Sarrat, A.; Guénard, H.; Demarquez, J. L.; Lara, Jacinto; Fayon, Michaël

doi:10.1016/s0761-8425(08)74978-7

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we based this definition on the recommendations provided by a current evidence-based CPG, there is a gap in the literature for evaluating the actual appropriateness of bronchiolitis management for specific indications. For example, it has been reported that atopic dermatitis aggravates the allergic airways inflammation in patients with acute viral bronchiolitis [14]. Therefore, it is probable that treating patients with acute viral bronchiolitis and coexisting atopic dermatitis with corticosteroids could not be considered completely inappropriate.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

Sarmiento

Rojas-Soto

Rodríguez‐Martínez

2017

BioMed Research International

View full text Add to dashboard Cite

Background The aim of the present study was to determine predictors of inappropriate use of diagnostic tests and management of bronchiolitis in a population of hospitalized infants. Methods In an analytical cross-sectional study, we determined independent predictors of the inappropriate use of diagnostic tests and management of bronchiolitis in a population of hospitalized infants. We defined a composite outcome score as the main outcome variable. Results Of the 303 included patients, 216 (71.3%) experienced an inappropriate use of diagnostic tests and treatment of bronchiolitis. After controlling for potential confounders, it was found that atopic dermatitis (OR 5.30; CI 95% 1.14–24.79; p = 0.034), length of hospital stay (OR 1.48; CI 95% 1.08–2.03; p = 0.015), and the number of siblings (OR 1.92; CI 95% 1.13–3.26; p = 0.015) were independent predictors of an inappropriate use of diagnostic tests and treatment of the disease. Conclusions Inappropriate use of diagnostic tests and treatment of bronchiolitis was a highly prevalent outcome in our population of study. Participants with atopic dermatitis, a longer hospital stay, and a greater number of siblings were at increased risk for inappropriate use of diagnostic tests and management of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

Sarmiento

Rojas-Soto

Rodríguez‐Martínez

2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…34 Interestingly, supporting this practice, there is evidence showing that atopic dermatitis aggravates allergic airways inflammation in patients with acute viral bronchiolitis. 36 All this evidence collectively suggests that infants suffering from viral bronchiolitis with clinical characteristics such as atopic dermatitis or a family history of asthma in a first-degree relative could benefit from therapy with albuterol.…”

Section: Discussionmentioning

confidence: 99%

For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?

Rodríguez‐Martínez

Niño

Castro-Rodriguez

et al. 2021

aei

View full text Add to dashboard Cite

Although there is increasing evidence showing that infants with viral bronchiolitis exhibit a high degree of heterogeneity, a core uncertainty shared by many clinicians is with regard to understanding which patients are most likely to benefit from bronchodilators such as albuterol. Based on our review, we concluded that older infants with rhinovirus (RV) bronchiolitis, especially those with a nasopharyngeal microbiome dominated by Haemophilus influenzae; those affected during nonpeak months or during non-respiratory syncytial virus (RSV) predominant months; those with wheezing at presentation; those with clinical characteristics such as atopic dermatitis or a family history of asthma in a first-degree relative; and those infants infected with RSV genotypes ON1 and BA, have the greatest likelihood of benefiting from albuterol. Presently, this patient profile could serve as the basis for rational albuterol administration in patients with viral bronchiolitis, at least on a therapeutic trial basis, and it could also be the starting point for future targeted randomized clinical trials (RCTs) on the use of albuterol among a subset of infants with bronchiolitis.

show abstract

“…Notably, the lack of adherence to these recommendations was mainly due to the use of β 2 -AR agonists (in 89.4% of patients) [67]. There is also evidence showing that atopic dermatitis aggravates allergic airway inflammation in patients with acute viral bronchiolitis [68]. Notably, there is strong evidence suggesting that the interplay between early viral infection and the development of airway hyperreactivity and asthma is also influenced by the individual genetic background.…”

Section: Host Factors Potentially Linked To Asm Hyperactivity and β 2mentioning

confidence: 99%

The use of β₂-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines

2020

View full text Add to dashboard Cite

Despite scientific evidence proving that inhaled β2-adrenergic receptor (β2-AR) agonists can reverse bronchoconstriction in all ages, current guidelines advocate against the use of β2-AR bronchodilators in infants with viral bronchiolitis because clinical trials have not demonstrated an overall clinical benefit. However, there are many different types of viral bronchiolitis, with variations occurring at an individual and viral level. To discard a potentially helpful treatment from all children regardless of their clinical features may be unwarranted. Unfortunately, the clinical criteria to identify the infants that may benefit from bronchodilators from those who do not are not clear. Thus, we summarised the current understanding of the individual factors that may help clinicians determine the highest probability of response to β2-AR bronchodilators during viral bronchiolitis, based on the individual immunobiology, viral pathogen, host factors and clinical presentation.

show abstract

La dermatite atopique aggrave l’inflammation allergique dans la bronchiolite aiguë virale

Cited by 4 publications

References 31 publications

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?

The use of β₂-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines

Contact Info

Product

Resources

About

La dermatite atopique aggrave l’inflammation allergique dans la bronchiolite aiguë virale

Cited by 4 publications

References 31 publications

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis

For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?

The use of β2-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines

Contact Info

Product

Resources

About

The use of β₂-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines